Concepts (75)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiopulmonary Bypass | 2 | 2004 | 57 | 0.300 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2006 | 22 | 0.290 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2006 | 9 | 0.290 |
Why?
|
| Ibuprofen | 1 | 2005 | 4 | 0.280 |
Why?
|
| Drug Hypersensitivity | 1 | 2005 | 8 | 0.280 |
Why?
|
| Heart Defects, Congenital | 2 | 2004 | 28 | 0.270 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 71 | 0.260 |
Why?
|
| Plasma | 1 | 2004 | 15 | 0.260 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2005 | 145 | 0.250 |
Why?
|
| Influenza, Human | 1 | 2006 | 122 | 0.250 |
Why?
|
| Blood Transfusion | 1 | 2004 | 64 | 0.250 |
Why?
|
| NF-kappa B | 1 | 2002 | 75 | 0.210 |
Why?
|
| Myocardium | 1 | 2002 | 170 | 0.200 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2014 | 23 | 0.190 |
Why?
|
| Hyaluronic Acid | 1 | 2020 | 45 | 0.180 |
Why?
|
| Muscle Development | 1 | 2020 | 45 | 0.180 |
Why?
|
| Adult Stem Cells | 1 | 2020 | 24 | 0.180 |
Why?
|
| Heparin | 1 | 2020 | 75 | 0.180 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 100 | 0.170 |
Why?
|
| Hydrogels | 1 | 2020 | 103 | 0.170 |
Why?
|
| Child, Preschool | 4 | 2014 | 1167 | 0.140 |
Why?
|
| Infant, Newborn | 3 | 2014 | 598 | 0.130 |
Why?
|
| Patient Admission | 1 | 2014 | 53 | 0.120 |
Why?
|
| Critical Illness | 1 | 2014 | 87 | 0.120 |
Why?
|
| Infant | 3 | 2014 | 969 | 0.120 |
Why?
|
| Purpura Fulminans | 1 | 2011 | 4 | 0.100 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 24 | 0.100 |
Why?
|
| Staphylococcal Infections | 1 | 2011 | 57 | 0.100 |
Why?
|
| Male | 6 | 2020 | 17807 | 0.090 |
Why?
|
| Humans | 7 | 2020 | 29093 | 0.080 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 21 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2006 | 78 | 0.070 |
Why?
|
| Heart Arrest | 1 | 2006 | 39 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2006 | 60 | 0.070 |
Why?
|
| Hypotension | 1 | 2005 | 47 | 0.070 |
Why?
|
| Female | 4 | 2014 | 18164 | 0.060 |
Why?
|
| Troponin I | 1 | 2004 | 17 | 0.060 |
Why?
|
| Complement C3 | 1 | 2004 | 7 | 0.060 |
Why?
|
| Acute-Phase Proteins | 1 | 2004 | 10 | 0.060 |
Why?
|
| Child | 2 | 2014 | 2219 | 0.060 |
Why?
|
| Erythrocyte Transfusion | 1 | 2004 | 32 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2004 | 49 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 97 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2004 | 71 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 493 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2004 | 225 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2004 | 131 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2004 | 501 | 0.060 |
Why?
|
| Length of Stay | 1 | 2004 | 292 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2002 | 9 | 0.050 |
Why?
|
| Endotoxins | 1 | 2002 | 36 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 200 | 0.050 |
Why?
|
| Nerve Regeneration | 1 | 2020 | 40 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2004 | 670 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2020 | 106 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 272 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2020 | 276 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 92 | 0.040 |
Why?
|
| Inflammation | 1 | 2002 | 507 | 0.040 |
Why?
|
| Adult | 2 | 2020 | 8420 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 203 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2020 | 436 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2004 | 3099 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2002 | 2019 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2014 | 332 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 2402 | 0.030 |
Why?
|
| Vancomycin | 1 | 2011 | 19 | 0.030 |
Why?
|
| Clindamycin | 1 | 2011 | 18 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 273 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 1687 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 2001 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 285 | 0.020 |
Why?
|
| Animals | 1 | 2020 | 7297 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 430 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 3111 | 0.020 |
Why?
|